Key result
Adding nebivolol to standard treatment after revascularization for severe renal artery stenosis increased eGFR from 44.8 to 50.6 ml/min at 6 months, whereas eGFR did not change in the control group.
Why the study?
Does nebivolol improve estimated glomerular filtration rate in patients with severe renal artery stenosis who underwent revascularization?
RCT (n=33)
Randomized
Does nebivolol improve estimated glomerular filtration rate in patients with severe renal artery stenosis who underwent revascularization?
The addition of nebivolol to standard antihypertensive therapy after revascularization for severe renal artery stenosis may improve renal function and reduce proteinuria.
Answers are grounded in this paper and cite their sources.
Nebivolol addition warrants consideration after renal revascularization; extends evidence for beta-blockers in renovascular disease.
Renal artery stenosis (RAS) is a progressive disease and may lead to chronic kidney disease by deterioration of renal functions. Endothelial dysfunction is an important causative factor for kidney damage after RAS revascularization. Nebivolol, a new generation beta blocker induces endothelium-related arterial relaxation by nitric oxide (NO) and may improve endothelial dysfunction. This pilot study tested the effect of nebivolol on the glomerular filtration rate (GFR) in a series of 33 patients with severe RAS (>70%) who underwent revascularization. After revascularization, nebivolol was added to antihypertensive treatment in 17 randomly selected patients while 16 patients (control group) continued their standard treatment. Estimated glomerular filtration rate (eGFR), proteinuria as well as nitrite and nitrate levels were measured at baseline and 6 months after the revascularization procedure. Six months after revascularization, eGFR increased from 44.8 to 50.6 ml/min in the nebivolol group. In contrast, eGFR did not change in the control group. Nitrite/nitrate levels decreased to a significant extent both in the nebivolol and in the control group. Proteinuria decreased more in the nebivolol group compared to the control group. These pilot data support a full-fledged clinical trial, testing whether nebivolol may be beneficial in the post-revascularization phase in patients with RAS.
No takes yet. Share an insight, caveat, or question.
Duranay et al. (2009) conducted an RCT in Severe renal artery stenosis (n=33). Nebivolol vs. Standard treatment was evaluated on Estimated glomerular filtration rate (eGFR). Adding nebivolol to standard treatment after revascularization for severe renal artery stenosis increased eGFR from 44.8 to 50.6 ml/min at 6 months, whereas eGFR did not change in the control group.
Synapse has enriched 10 related papers. Consider them for comparative context: